PL2328414T3 - Podstawione pochodne triazolo-pirydazyny - Google Patents

Podstawione pochodne triazolo-pirydazyny

Info

Publication number
PL2328414T3
PL2328414T3 PL09810685T PL09810685T PL2328414T3 PL 2328414 T3 PL2328414 T3 PL 2328414T3 PL 09810685 T PL09810685 T PL 09810685T PL 09810685 T PL09810685 T PL 09810685T PL 2328414 T3 PL2328414 T3 PL 2328414T3
Authority
PL
Poland
Prior art keywords
pyridazine derivatives
substituted triazolo
triazolo
substituted
pyridazine
Prior art date
Application number
PL09810685T
Other languages
English (en)
Polish (pl)
Inventor
Scott Harbeson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of PL2328414T3 publication Critical patent/PL2328414T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09810685T 2008-08-29 2009-08-28 Podstawione pochodne triazolo-pirydazyny PL2328414T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9329308P 2008-08-29 2008-08-29
PCT/US2009/055427 WO2010025407A1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives
EP20090810685 EP2328414B1 (en) 2008-08-29 2009-08-28 Substituted triazolo-pyridazine derivatives

Publications (1)

Publication Number Publication Date
PL2328414T3 true PL2328414T3 (pl) 2014-05-30

Family

ID=41721962

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09810685T PL2328414T3 (pl) 2008-08-29 2009-08-28 Podstawione pochodne triazolo-pirydazyny

Country Status (17)

Country Link
US (4) US8003646B2 (enExample)
EP (2) EP2716158A1 (enExample)
JP (3) JP5183808B2 (enExample)
KR (1) KR20110063479A (enExample)
CN (2) CN102176826B (enExample)
AU (1) AU2009285533B2 (enExample)
BR (1) BRPI0912928A2 (enExample)
CA (1) CA2735549A1 (enExample)
DK (1) DK2328414T3 (enExample)
EA (1) EA020071B1 (enExample)
ES (1) ES2451542T3 (enExample)
HR (1) HRP20140195T1 (enExample)
MX (1) MX2011002278A (enExample)
PL (1) PL2328414T3 (enExample)
PT (1) PT2328414E (enExample)
WO (1) WO2010025407A1 (enExample)
ZA (1) ZA201102123B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011002278A (es) 2008-08-29 2011-04-14 Concert Pharmaceuticals Inc Derivados de triazolo-piridazina sustituidos.
EP2340782A4 (en) 2008-10-03 2014-04-02 Inst Alberto Luiz Coimbra De Pos Graduacao E Pesquisa De Engenharia Coppe Ufrj METHOD AND DEVICE FOR REMOVING METAL FRAGMENTS AND METAL ELEMENTS FROM TOOTH ROOT CHANNELS
JP2012531419A (ja) 2009-06-23 2012-12-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｇａｂａ−ａ受容体修飾物質としての重水素修飾されたトリアゾロピリダジン誘導体
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
KR20140077964A (ko) * 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
BR112014016930A8 (pt) 2012-01-11 2017-12-26 Bayer Ip Gmbh compostos tetrazol-5-il- e triazol-5-il-arila e uso destes como herbicidas
US20150099753A1 (en) * 2012-05-11 2015-04-09 Concert Pharmaceuticals Inc. Form 5 polymorph of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
JP2015516440A (ja) * 2012-05-11 2015-06-11 コンサート ファーマシューティカルズ インコーポレイテッド ７−（ｔｅｒｔ−ブチル−ｄ９）−３−（２，５−ジフルオロフェニル）−６−（（１−メチル−１Ｈ−１，２，４−トリアゾール−５−イル）メトキシ）−［１，２，４］トリアゾロ［４，３−ｂ］ピリダジンの２型多形
US20150158870A1 (en) * 2012-05-11 2015-06-11 Concert Pharmaceuticals Inc. Polymorphs of 7-(tert-butyl-d9)-3-(2,5-difluorophenyl)-6-((1-methyl-1h-1,2,4-triazol-5-yl)methoxy)-[1,2,4]triazolo[4,3-b]pyridazine
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015095549A1 (en) * 2013-12-18 2015-06-25 Concert Pharmaceuticals, Inc. Dosage regimen for gabaa receptor subtype selective drug
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
CN104474549A (zh) * 2014-11-24 2015-04-01 王寿世 异丙酚和gabaa受体拮抗剂在制备麻醉药物中的用途
CN104353078B (zh) * 2014-11-24 2017-10-24 王寿世 一种麻醉用药物组合物
US10026332B1 (en) 2017-04-10 2018-07-17 Jasmine Gupta Method to deliver contextual educational information utilizing smart wearables
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321162D0 (en) 1993-10-13 1993-12-01 Boots Co Plc Therapeutic agents
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
AU707748B2 (en) 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
IL127911A0 (en) * 1996-07-25 1999-11-30 Merck Sharp & Dohme Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
MXPA00007135A (es) * 1998-01-21 2002-11-07 Merck Sharp & Dohme Derivados de triazolo-piridazina como ligandos para receptores gaba.
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ES2232416T3 (es) * 1999-01-27 2005-06-01 MERCK SHARP & DOHME LTD. Derivados de triazolo-piridazina como ligandos para receptores gaba.
ES2193921T3 (es) 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
DE60315876T2 (de) * 2002-11-28 2008-05-21 Neurosearch A/S Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
WO2006061428A2 (en) 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US7598273B2 (en) 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CN101594870A (zh) * 2006-08-22 2009-12-02 康塞特医药品有限公司 4-氨基喹唑啉衍生物及其使用方法
EP2059241A1 (en) 2006-09-05 2009-05-20 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
BRPI0809171A2 (pt) * 2007-04-02 2014-09-16 Auspex Pharmaceuticals Inc "composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
MX2011002278A (es) * 2008-08-29 2011-04-14 Concert Pharmaceuticals Inc Derivados de triazolo-piridazina sustituidos.

Also Published As

Publication number Publication date
AU2009285533A1 (en) 2010-03-04
JP5183808B2 (ja) 2013-04-17
WO2010025407A1 (en) 2010-03-04
MX2011002278A (es) 2011-04-14
US20150111895A1 (en) 2015-04-23
CN104098578A (zh) 2014-10-15
US8003646B2 (en) 2011-08-23
AU2009285533A2 (en) 2011-04-21
EP2716158A1 (en) 2014-04-09
JP2014058518A (ja) 2014-04-03
ES2451542T3 (es) 2014-03-27
JP2012501346A (ja) 2012-01-19
JP2013100322A (ja) 2013-05-23
ZA201102123B (en) 2011-12-28
HRP20140195T1 (hr) 2014-04-11
KR20110063479A (ko) 2011-06-10
US8921366B2 (en) 2014-12-30
EA201100409A1 (ru) 2011-10-31
CA2735549A1 (en) 2010-03-04
PT2328414E (pt) 2014-03-17
US20100056529A1 (en) 2010-03-04
EP2328414A1 (en) 2011-06-08
JP5373982B2 (ja) 2013-12-18
US20130225590A1 (en) 2013-08-29
EP2328414A4 (en) 2011-11-16
DK2328414T3 (en) 2014-03-10
AU2009285533B2 (en) 2014-02-13
BRPI0912928A2 (pt) 2015-08-04
EA020071B1 (ru) 2014-08-29
US8399467B2 (en) 2013-03-19
US20120004236A1 (en) 2012-01-05
CN102176826A (zh) 2011-09-07
CN102176826B (zh) 2014-08-20
EP2328414B1 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
ZA201102123B (en) Substituted triazolo-pyridazine derivatives
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
SI2767536T1 (sl) Derivati izoksazolo-piridina
ZA201102449B (en) Morpholinopurine derivatives
IL202020A0 (en) Spiroindolinone derivatives
ZA201006104B (en) Substituted xanthine derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
IL202830A0 (en) Indazolamide derivatives
ZA201001058B (en) Quinazolinamide derivatives
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
IL211241A0 (en) 7-azaindole derivatives
ZA201101236B (en) New 2-amidothiadiazole derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL207192A0 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201105050B (en) Quinazolinamide derivatives
IL207191A0 (en) Substituted heteroaylamide oxazepyrimidone derivatives
IL202667A0 (en) Isoxazole-imidazole derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
EP2133347A4 (en) 1-BIARYLAZETIDINONDERIVATE